Ovarian Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with ovarian clear cell carcinoma, confirmed by laboratory testing of tissue samples.
- People whose cancer has continued to grow (shown on imaging) after receiving immunotherapy treatments (such as anti-PD-1, PD-L1, or PD-1/PD-L1+CTLA4), and who have since received a treatment called Sacituzumab.
- People who have at least one tumour that can be measured using standard imaging criteria (called RECIST version 1.1).
- People with a life expectancy of at least 12 months.
- People with normal kidney and liver function, and no significant suppression of bone marrow activity.
- People with a good general level of physical functioning, rated 0 or 1 on a standard scale used by doctors (called the ECOG Performance Status scale).
- People who have recovered from side effects of previous treatments, so that those side effects are at a mild or absent level (below grade 1, except for hair loss, which is permitted).
- People who are willing to take part, follow the study requirements, attend scheduled visits, and sign a consent form agreeing to participate.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have received more than two rounds of treatment after their cancer stopped responding to immunotherapy.
- People who have previously been treated with a drug called irinotecan, or with antibody-drug treatments (ADCs) that contain a type of ingredient known as topoisomerase I inhibitors.
- People who have, or have had, a lung condition called interstitial lung disease (ILD) or non-infectious pneumonitis that required treatment with steroids.
- People with a significant dry eye condition, a serious eyelid gland disease, severe eyelid inflammation (blepharitis), or a history of corneal disease that affects normal eye healing.
- People who currently have, or have a history of, a blocked or obstructed bowel, a bowel fistula, a blocked urinary tract that cannot be managed with a stent, inflammatory bowel disease, or cancer that has spread to the brain.
- People who have received an organ transplant.
- People with a serious (grade 3 or higher) blood clot in a vein.
- People with any active infection of any severity, including tuberculosis.
- People who have previously had radiation therapy to the pelvis or abdomen.
- People who currently have another type of cancer at the same time.
- People with significant mental health conditions affecting their mental status.
- People who are pregnant or breastfeeding, or people of childbearing potential (male or female) who are unable to use effective contraception during the study and for 6 months after the last dose.
- People the trial investigator considers unsuitable for participation for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jing Li, Doctor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phone: +8615868090553
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Objective response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.